Johnson & Johnson (JNJ)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-08
$267.34+3.09%
Close 2026-07-07 · 1-day change
Reading JNJ? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track JNJ free→NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-08
Reading JNJ? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track JNJ free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Johnson & Johnson's growth depends on its strong revenue trajectory and recent investments. Revenue grew 9.9% year over year, and the last quarter beat expectations. It trades at 24× P/E versus a peer median of 26×. The market is pricing in more growth than we forecast, indicating high expectations. A specific risk is the potential for a credibility hit if guidance is cut. Peer multiples imply a price about 50% below where it trades; this read is provisional.
Trailing returns as of 2026-07-07. JNJ is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 23 analysts currently covering JNJ (as of Jul 2026).
Based on 8 Wall Street analysts offering 12-month price targets for JNJ in the last 4 months.
A consensus fair price across 13 valuation methods, at three horizons. Current price $267.34. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
FDA approval supports growth in medical device revenue.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-07. EPS is implied from price ÷ P/E. Not investment advice.
Current $267.34
The last 12 months of price, then the range of analyst 12-month targets from today’s $267.34.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
New platform enhances J&J's competitive position in cardiology.
New data supports product expansion and revenue growth potential.
New product supports growth and revenue objectives.
New data could expand market for gMG treatment.
CEO's message indicates potential growth in a new market.
Focus on oncology and rare diseases supports revenue goals.
Legal payout may indicate ongoing litigation risks.
